Corticotropin
drug drugOn this page
Also known as ActhActharActhar gelActhar gel (autoinjector)AdrenocorticotrophinAdrenocorticotropic hormoneAdrenocorticotropinAdrenomoneCorticotrophinCorticotropin (acth)Corticotropin in gelatin matrixrepositoryCorticotropinaCorticotropineCortigelCortrophinH.p. acthar gelPurified cortrophin gelRepository corticotropin
Summary
Corticotropin (CHEMBL1201610) is an approved unknown (ATC H01AA01) targeting MC1R, MC3R, and MC4R; indicated across 23 conditions including multiple sclerosis and rheumatoid arthritis.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: H01AA01
- Targets: 4 (MC1R, MC3R, MC4R…)
- Indications: 23 conditions
- Clinical trials: 77
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201610 |
| Name | Corticotropin |
| Type | Unknown |
| Max phase | 4 |
| ATC | H01AA01 |
Also known as: Acth, Acthar, Acthar gel, Acthar gel (autoinjector), Adrenocorticotrophin, Adrenocorticotropic hormone, Adrenocorticotropin, Adrenomone, Corticotrophin, Corticotropin, Corticotropin (acth), Corticotropin in gelatin matrix
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| MC1R | MC1 receptor | Agonist | 8.6 | 1% | Q01726 |
| MC3R | MC3 receptor | Agonist | 7.06 | 0.1% | P41968 |
| MC4R | MC4 receptor | Agonist | 6.16 | 0% | P32245 |
| MC5R | MC5 receptor | Agonist | 5 | 0% | P33032 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 4 target gene(s): MC1R, MC3R, MC4R, MC5R.
Top Reactome pathways
10 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Developmental Biology | 4 | MC1R, MC3R, MC4R, MC5R |
| Signal Transduction | 4 | MC1R, MC3R, MC4R, MC5R |
| Signaling by GPCR | 4 | MC1R, MC3R, MC4R, MC5R |
| Class A/1 (Rhodopsin-like receptors) | 4 | MC1R, MC3R, MC4R, MC5R |
| Peptide ligand-binding receptors | 4 | MC1R, MC3R, MC4R, MC5R |
| GPCR downstream signalling | 4 | MC1R, MC3R, MC4R, MC5R |
| G alpha (s) signalling events | 4 | MC1R, MC3R, MC4R, MC5R |
| GPCR ligand binding | 4 | MC1R, MC3R, MC4R, MC5R |
| MITF-M-regulated melanocyte development | 4 | MC1R, MC3R, MC4R, MC5R |
| Transcriptional and post-translational regulation of MITF-M expression and activity | 4 | MC1R, MC3R, MC4R, MC5R |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| adenylate cyclase-activating G protein-coupled receptor signaling pathway | 4 |
| signal transduction | 4 |
| G protein-coupled receptor signaling pathway | 4 |
| G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger | 3 |
| regulation of feeding behavior | 3 |
| phospholipase C-activating G protein-coupled receptor signaling pathway | 2 |
| adenylate cyclase-modulating G protein-coupled receptor signaling pathway | 2 |
| UV protection | 1 |
| sensory perception of pain | 1 |
| negative regulation of tumor necrosis factor production | 1 |
| intracellular signal transduction | 1 |
| melanin biosynthetic process | 1 |
| pigmentation | 1 |
| positive regulation of transcription by RNA polymerase II | 1 |
| positive regulation of melanin biosynthetic process | 1 |
Indications & clinical
Indications
1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).
| Indication | Phase | MONDO | EFO |
|---|---|---|---|
| multiple sclerosis | 4 | MONDO:0005301 | MONDO:0005301 |
18 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| rheumatoid arthritis | 3 | MONDO:0008383 | EFO:0000685 |
| relapsing-remitting multiple sclerosis | 3 | MONDO:0005314 | EFO:0003929 |
| nephrotic syndrome | 3 | MONDO:0005377 | EFO:0004255 |
| kidney disorder | 3 | MONDO:0005240 | EFO:0003086 |
| focal segmental glomerulosclerosis | 3 | MONDO:0100313 | EFO:0004236 |
| diabetic kidney disease | 2 | MONDO:0005016 | EFO:0000401 |
| uveitis | 2 | MONDO:0020283 | EFO:1001231 |
| dermatomyositis | 2 | MONDO:0016367 | EFO:0000398 |
| epilepsy | 2 | MONDO:0005027 | EFO:0000474 |
| primary progressive multiple sclerosis | 2 | MONDO:0000451 | EFO:0008520 |
| secondary progressive multiple sclerosis | 2 | MONDO:0000450 | EFO:0008522 |
| scleritis | 2 | MONDO:0001718 | MONDO:0001718 |
| amyotrophic lateral sclerosis | 2 | MONDO:0004976 | MONDO:0004976 |
| migraine disorder | 2 | MONDO:0005277 | MONDO:0005277 |
| sarcoidosis | 2 | MONDO:0019338 | MONDO:0019338 |
| chronic kidney disease | 1 | MONDO:0005300 | EFO:0003884 |
| membranous glomerulonephritis | 1 | MONDO:0005376 | EFO:0004254 |
| glomerulonephritis | 1 | MONDO:0002462 | MONDO:0002462 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 77.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 38 |
| Not specified | 18 |
| PHASE2/PHASE3 | 5 |
| PHASE3 | 5 |
| PHASE2 | 5 |
| PHASE1 | 3 |
| EARLY_PHASE1 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06964269 | PHASE4 | RECRUITING | Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease |
| NCT00854750 | PHASE4 | TERMINATED | Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis |
| NCT01021540 | PHASE4 | COMPLETED | Prospective Study Evaluating the Effect of Repository Corticotropin in the Treatment of Various Nephrotic Syndromes |
| NCT01028287 | PHASE4 | COMPLETED | Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN) |
| NCT01129284 | PHASE4 | COMPLETED | Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) |
| NCT01155141 | PHASE4 | COMPLETED | Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH |
| NCT01753401 | PHASE4 | COMPLETED | Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease |
| NCT01769937 | PHASE4 | COMPLETED | Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus |
| NCT01926054 | PHASE4 | WITHDRAWN | ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis |
| NCT01948388 | PHASE4 | COMPLETED | The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients |
| NCT02057523 | PHASE4 | TERMINATED | Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients |
| NCT02092883 | PHASE4 | COMPLETED | Evaluation of Neuroinflammation in Children With Infantile Spasms |
| NCT02188017 | PHASE4 | UNKNOWN | Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS) |
| NCT02226341 | PHASE4 | TERMINATED | ACTHar in the Treatment of Lupus Nephritis |
| NCT02245841 | PHASE4 | COMPLETED | Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis |
| NCT02298491 | PHASE4 | COMPLETED | Treatment of CNS Sarcoidosis With H.P. Acthar Gel |
| NCT02382523 | PHASE4 | WITHDRAWN | Acthar on Proteinuria in IgA Nephropathy Patients |
| NCT02399462 | PHASE4 | WITHDRAWN | Acthar for Treatment of Post-transplant FSGS |
| NCT02523092 | PHASE4 | TERMINATED | Use of CXCL9 as a Biomarker of Acthar Efficacy |
| NCT02541955 | PHASE4 | COMPLETED | Use of Acthar in Rheumatoid Arthritis (RA) Related Flares |
| NCT02546492 | PHASE4 | TERMINATED | Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar |
| NCT02633046 | PHASE4 | COMPLETED | Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria |
| NCT02769702 | PHASE4 | TERMINATED | Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis |
| NCT02919761 | PHASE4 | COMPLETED | Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis |
| NCT02953821 | PHASE4 | COMPLETED | Acthar Gel for Active Systemic Lupus Erythematosus (SLE) |
| NCT03021317 | PHASE4 | TERMINATED | Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses |
| NCT03025828 | PHASE4 | COMPLETED | Adrenocorticotropic Hormone in Membranous Nephropathy |
| NCT03066869 | PHASE4 | UNKNOWN | Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis |
| NCT03082573 | PHASE4 | UNKNOWN | Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel |
| NCT03126760 | PHASE4 | TERMINATED | Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS) |
| NCT03287635 | PHASE4 | COMPLETED | Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease |
| NCT03320070 | PHASE4 | COMPLETED | Acthar Gel in Participants With Pulmonary Sarcoidosis |
| NCT03408405 | PHASE4 | WITHDRAWN | ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children |
| NCT03419650 | PHASE4 | COMPLETED | Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS) |
| NCT03656692 | PHASE4 | TERMINATED | Safety and Effectiveness of Acthar Gel for Inflammation of the Eye’s Uvea (Middle Layer) |
| NCT04080076 | PHASE4 | WITHDRAWN | Comparative and Efficacy Study of ACTHar Gel Alone or in Combination With Tacrolimus in Fibrillary Glomerulopathy |
| NCT04169061 | PHASE4 | COMPLETED | Impact of Acthar on Everyday Life of Participants With Severe Keratitis |
| NCT05546047 | PHASE4 | UNKNOWN | A Study of Acthar Gel Alone or With Tacrolimus to Reduce Proteinuria in Fibrillary Glomerulopathy Patients |
| NCT05279118 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Ketogenic Diet vs ACTH for the Treatment of Children With West Syndrome |
| NCT06201897 | PHASE2/PHASE3 | RECRUITING | Cortical Excitability in West Syndrome Using Transcranial Magnetic Stimulation |
| NCT00947895 | PHASE2/PHASE3 | TERMINATED | Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone |
| NCT01062568 | PHASE3 | COMPLETED | The Adrenal Contribution to Androgen Production in Girls During Puberty |
| NCT02132195 | PHASE3 | COMPLETED | Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome |
| NCT02290444 | PHASE3 | COMPLETED | Effects of Acthar on Recovery From Cognitive Relapses in MS |
| NCT02315872 | PHASE3 | COMPLETED | ACTH for Fatigue in Multiple Sclerosis Patients |
| NCT02348905 | PHASE2/PHASE3 | UNKNOWN | ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial |
| NCT02683889 | PHASE3 | COMPLETED | Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation |
| NCT03068754 | PHASE2/PHASE3 | TERMINATED | Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS) |
| NCT07005154 | PHASE2 | RECRUITING | A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer |
| NCT00004758 | PHASE2 | COMPLETED | Phase II Randomized Study of Early Surgery Vs Multiple Sequential Antiepileptic Drug Therapy for Infantile Spasms Refractory to Standard Treatment |
| NCT01813591 | PHASE2 | COMPLETED | A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines |
| NCT01950234 | PHASE2 | TERMINATED | ACTH in Progressive Forms of MS |
| NCT01984268 | PHASE2 | TERMINATED | ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate |
| NCT00805753 | PHASE1 | COMPLETED | Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy |
| NCT01049451 | PHASE1 | COMPLETED | Pulse ACTH vs. MP for MS |
| NCT02486744 | PHASE1 | TERMINATED | Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population |
| NCT01987167 | EARLY_PHASE1 | COMPLETED | Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis |
| NCT03727776 | EARLY_PHASE1 | COMPLETED | Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR) |
| NCT03905603 | EARLY_PHASE1 | UNKNOWN | Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS |
| NCT00005890 | Not specified | COMPLETED | Diagnostic Study of Adrenal Cortical Function in Children With Septic Shock |
| NCT00950781 | Not specified | COMPLETED | Cortisol Levels on Menopausal Symptoms - Ancillary (Addendum) Study to Protocol 16997 |
| NCT00989781 | Not specified | COMPLETED | Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome |
| NCT01367964 | Not specified | UNKNOWN | Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH) |
| NCT01637064 | Not specified | UNKNOWN | Dermatomyositis and Polymyositis Registry |
| NCT01900093 | Not specified | UNKNOWN | Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses |
| NCT01906684 | Not specified | UNKNOWN | Comprehensive Analysis of Relapse in Multiple Sclerosis |
| NCT02006849 | Not specified | WITHDRAWN | ACTH Treatment of APOL1- Associated Nephropathy |
| NCT02030028 | Not specified | COMPLETED | ACTH Gel Therapy in Rheumatoid Arthritis |
| NCT02258217 | Not specified | COMPLETED | Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS) |
| NCT02434757 | Not specified | UNKNOWN | Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis |
| NCT02972346 | Not specified | UNKNOWN | Availability Study of ACTH to Treat Children SRNS/SDNS |
| NCT03042637 | Not specified | SUSPENDED | Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome |
| NCT03473964 | Not specified | UNKNOWN | (ACTH) for the Treatment of Sarcoid Uveitis |
| NCT03644771 | Not specified | UNKNOWN | Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function |
| NCT04306653 | Not specified | UNKNOWN | ACTH vs Betamethasone in Hospitalized Patients With Acute Gout |
| NCT04461535 | Not specified | COMPLETED | Corticotropin Stimulation in Adrenal Venous Sampling for Patients With Primary Aldosteronism(ADOPA) |
| NCT04808856 | Not specified | UNKNOWN | Treatment of Refractory Gout With ACTH or Methylprednisolone |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
174 molecules share ≥1 primary target. Top 100 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| AFAMELANOTIDE | ChEMBL + PubChem | Phase 4 (approved) | MC1R, MC3R, MC4R, MC5R |
| SETMELANOTIDE | ChEMBL + PubChem | Phase 4 (approved) | MC1R, MC3R, MC4R, MC5R |
| BREMELANOTIDE | ChEMBL | Phase 4 (approved) | MC1R, MC3R, MC4R, MC5R |
| INTERMEDINE | ChEMBL | Phase 2 | MC1R, MC3R, MC4R, MC5R |
| AMIODARONE | ChEMBL | Phase 4 (approved) | MC3R, MC4R, MC5R |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | MC3R, MC4R, MC5R |
| CHLORPROMAZINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R, MC5R |
| COLISTIN | ChEMBL | Phase 4 (approved) | MC3R, MC4R, MC5R |
| FLUPHENAZINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R, MC5R |
| MICONAZOLE | ChEMBL | Phase 4 (approved) | MC3R, MC4R, MC5R |
| SERTRALINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R, MC5R |
| TAMOXIFEN | ChEMBL | Phase 4 (approved) | MC3R, MC4R, MC5R |
| CLOZAPINE | ChEMBL + PubChem | Phase 4 (approved) | MC3R, MC4R |
| CRIZOTINIB | ChEMBL + PubChem | Phase 4 (approved) | MC3R, MC4R |
| DESLORATADINE | ChEMBL + PubChem | Phase 4 (approved) | MC3R, MC4R |
| Ivacaftor | ChEMBL + PubChem | Phase 4 (approved) | MC3R, MC4R |
| Linagliptin | ChEMBL + PubChem | Phase 4 (approved) | MC3R, MC4R |
| PIMOZIDE | ChEMBL + PubChem | Phase 4 (approved) | MC3R, MC4R |
| PYRAZINAMIDE | ChEMBL + PubChem | Phase 4 (approved) | MC3R, MC4R |
| TEGASEROD | ChEMBL + PubChem | Phase 4 (approved) | MC3R, MC4R |
| AMITRIPTYLINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| AMLODIPINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| ANTAZOLINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| BEPRIDIL | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| BOSUTINIB | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| CARVEDILOL | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| CHLORHEXIDINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| CLEMASTINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| CLOMIPRAMINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| DULOXETINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| ECONAZOLE | ChEMBL | Phase 4 (approved) | MC3R, MC5R |
| FENOTEROL | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| FLUSPIRILENE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| GRAMICIDIN | ChEMBL | Phase 4 (approved) | MC4R, MC5R |
| HALOPERIDOL | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| IMIPRAMINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| LIDOCAINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| MEFLOQUINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| MITOXANTRONE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| MODAFINIL | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| NAFARELIN | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| PROCHLORPERAZINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| PROMETHAZINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| RIFAXIMIN | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| RIMONABANT | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| ROSIGLITAZONE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| TERFENADINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| THIORIDAZINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| TRIFLUOPERAZINE | ChEMBL | Phase 4 (approved) | MC3R, MC4R |
| PL-8177 | ChEMBL | Phase 2 | MC1R, MC4R |
| Abiraterone | PubChem | Approved | MC3R, MC4R |
| Aclidinium Bromide | PubChem | Approved | MC3R, MC4R |
| Acyclovir | PubChem | Approved | MC3R, MC4R |
| Allopurinol | PubChem | Approved | MC3R, MC4R |
| Alogliptin | PubChem | Approved | MC3R, MC4R |
| Amiloride | PubChem | Approved | MC3R, MC4R |
| Anagrelide | PubChem | Approved | MC3R, MC4R |
| Aprepitant | PubChem | Approved | MC3R, MC4R |
| Atazanavir | PubChem | Approved | MC3R, MC4R |
| Betamethasone Valerate | PubChem | Approved | MC3R, MC4R |
| Bosentan | PubChem | Approved | MC3R, MC4R |
| Clofarabine | PubChem | Approved | MC3R, MC4R |
| Dacarbazine | PubChem | Approved | MC3R, MC4R |
| Desoxycorticosterone Pivalate | PubChem | Approved | MC3R, MC4R |
| Didanosine | PubChem | Approved | MC3R, MC4R |
| Dihydroergotamine | PubChem | Approved | MC3R, MC4R |
| Docetaxel | PubChem | Approved | MC3R, MC4R |
| Erythromycin | PubChem | Approved | MC3R, MC4R |
| Ethambutol | PubChem | Approved | MC3R, MC4R |
| Fidaxomicin | PubChem | Approved | MC3R, MC4R |
| Glycopyrrolate | PubChem | Approved | MC3R, MC4R |
| Methotrexate | PubChem | Approved | MC3R, MC4R |
| Moxifloxacin | PubChem | Approved | MC3R, MC4R |
| Naproxen | PubChem | Approved | MC3R, MC4R |
| Olanzapine | PubChem | Approved | MC3R, MC4R |
| Olmesartan Medoxomil | PubChem | Approved | MC3R, MC4R |
| Pramipexole | PubChem | Approved | MC3R, MC4R |
| Propoxyphene | PubChem | Approved | MC3R, MC4R |
| rifampin | PubChem | Approved | MC3R, MC4R |
| Sildenafil | PubChem | Approved | MC3R, MC4R |
| Spectinomycin | PubChem | Approved | MC3R, MC4R |
| Sulindac | PubChem | Approved | MC3R, MC4R |
| Tadalafil | PubChem | Approved | MC3R, MC4R |
| Tamsulosin | PubChem | Approved | MC3R, MC4R |
| Tiotropium Bromide Monohydrate | PubChem | Approved | MC3R, MC4R |
| Valacyclovir | PubChem | Approved | MC3R, MC4R |
| Valganciclovir | PubChem | Approved | MC3R, MC4R |
| Vancomycin | PubChem | Approved | MC3R, MC4R |
| AFATINIB | ChEMBL + PubChem | Phase 4 (approved) | MC3R |
| CINACALCET | ChEMBL + PubChem | Phase 4 (approved) | MC3R |
| DACOMITINIB | ChEMBL + PubChem | Phase 4 (approved) | MC3R |
| GEFITINIB | ChEMBL + PubChem | Phase 4 (approved) | MC3R |
| BAZEDOXIFENE | ChEMBL | Phase 4 (approved) | MC3R |
| CAFFEINE | ChEMBL | Phase 4 (approved) | MC3R |
| CANNABIDIOL | ChEMBL | Phase 4 (approved) | MC3R |
| CHLORPROTHIXENE | ChEMBL | Phase 4 (approved) | MC3R |
| CISPLATIN | ChEMBL | Phase 4 (approved) | MC5R |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | MC4R |
| COSYNTROPIN | ChEMBL | Phase 4 (approved) | MC4R |
| DAUNORUBICIN | ChEMBL | Phase 4 (approved) | MC3R |
Related Atlas pages
- Genes: MC1R, MC3R, MC4R, MC5R
- Indicated for: multiple sclerosis
- In clinical trials for: rheumatoid arthritis, relapsing-remitting multiple sclerosis, nephrotic syndrome, kidney disorder, focal segmental glomerulosclerosis, diabetic kidney disease, uveitis, dermatomyositis, epilepsy, primary progressive multiple sclerosis, secondary progressive multiple sclerosis, scleritis, amyotrophic lateral sclerosis, migraine disorder, sarcoidosis
- Drugs: Afamelanotide, Setmelanotide, Bremelanotide, Amiodarone, Astemizole, Chlorpromazine, Colistin, Fluphenazine, Miconazole, Sertraline, Tamoxifen, Clozapine, Crizotinib, Desloratadine, Ivacaftor, Linagliptin, Pimozide, Pyrazinamide, Tegaserod, Amitriptyline, Amlodipine, Antazoline, Bepridil, Bosutinib, Carvedilol, Chlorhexidine, Clemastine, Clomipramine, Duloxetine, Econazole, Fenoterol, Fluspirilene, Gramicidin, Haloperidol, Imipramine, Lidocaine, Mefloquine, Mitoxantrone, Modafinil, Nafarelin, Prochlorperazine, Promethazine, Rifaximin, Rimonabant, Rosiglitazone, Terfenadine, Thioridazine, Trifluoperazine, Abiraterone, Aclidinium Bromide, Acyclovir, Allopurinol, Alogliptin, Amiloride, Anagrelide, Aprepitant, Atazanavir, Betamethasone Valerate, Bosentan, Clofarabine, Dacarbazine, Desoxycorticosterone Pivalate, Didanosine, Dihydroergotamine, Docetaxel, Erythromycin, Ethambutol, Fidaxomicin, Glycopyrrolate, Methotrexate, Moxifloxacin, Naproxen, Olanzapine, Olmesartan Medoxomil, Pramipexole, Propoxyphene, rifampin, Sildenafil, Spectinomycin, Sulindac, Tadalafil, Tamsulosin, Valacyclovir, Valganciclovir, Vancomycin, Afatinib, Cinacalcet, Dacomitinib, Gefitinib, Bazedoxifene, Caffeine, Cannabidiol, Chlorprothixene, Cisplatin, Clotrimazole, Cosyntropin, Daunorubicin